STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
117
13F, latest reported quarter
What the filings say about CLBT
Insiders, 180 days
-$5.4M net sold
4 sellers · 7% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$6.8M
8 notices
Cellebrite DI insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cellebrite DI Ltd. insiders sold a net $5.4M of stock across 15 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 12, 2026.
The trade is 3.3% of the 765,249 shares held after it.
2 other insiders sold within 30 days.
117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Hogan Thomas E. sold about $285.7K of CLBT on Aug 25, 2026; 2 other insiders sold within 30 days and 117 funds added in the latest 13F quarter.
5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 21, 2026.
The trade is 3.2% of the 135,281 shares held after it.
2 other insiders sold within 30 days.
117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Marketing Officer GEE DAVID NICHOLAS sold about $49.1K of CLBT under a 10b5-1 plan on Aug 24, 2026; 2 other insiders sold within 30 days and 117 funds added in the latest 13F quarter.
4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 12, 2026.
The trade is 1.6% of the 139,604 shares held after it.
2 other insiders sold within 30 days.
117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Marketing Officer GEE DAVID NICHOLAS sold about $24.7K of CLBT on Aug 21, 2026; 2 other insiders sold within 30 days and 117 funds added in the latest 13F quarter.
3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 12, 2026.
The trade is 2.9% of the 427,128 shares held after it.
2 other insiders sold within 30 days.
117 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Global Chief Revenue Officer Jewell Marcus sold about $141.2K of CLBT on Aug 21, 2026; 2 other insiders sold within 30 days and 117 funds added in the latest 13F quarter.
15 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
CLBT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
David Barter
Filed 2026-10-07
$267.2K
/s/ THOMAS E. HOGAN
Filed 2026-08-24
$714.6K
DAVID GEE
Filed 2026-08-24
$47.8K
MARCUS JEWELL
Filed 2026-08-19
$331.2K
DAVID NICHOLAS GEE
Filed 2026-08-19
$59.2K
CLBT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Brown Capital Management International Small Company Fund
$13.9M position · as of 2026-06-30
2.0%
International Small Company Fund
$3.6M position · as of 2026-05-31
1.0%
iShares MSCI Israel ETF
$3.6M position · as of 2026-05-31
0.4%
Victory Small Cap Stock Fund
$3.3M position · as of 2026-07-31
0.3%
International Opportunities Fund
$1.4M position · as of 2026-05-31
0.2%
International Small-Mid Cap Fund
$1.1M position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.4M sold by insiders over 180 days, 117 funds added last quarter, $6.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
fewer than four consecutive quarters of net income
Return on equity CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.9B
market value at close 2026-10-23 on 2026-02-23 shares, plus long-term debt only, 2025-06-30, minus cash 2025-12-31
Enterprise value CLBT
FY Dec 2025
$4.2B
FY Dec 2024
$4.3B
FY Dec 2023
$1.5B
FY Dec 2022
$739.8M
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing CLBT
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
none filed
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
CLBT ranks highest on financial health (78th percentile) and growth (69th), and lowest on insider conviction (17th), among Software & IT peers.
Financial health
78
Inputs
Debt to equity0.01x · 78 pct, sector of 288
Cash flow to debtneeds four quarters of operating cash flow
Growth
69
Inputs
Revenue growth, YoY+18.6% · 69 pct, sector of 480
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
17
Inputs
Net Form 4 buying (codes P and S), 180d-$5.3M · 33 pct, sector of 285
Insider buyers, 180d0 · 0 pct, sector of 290
Institutional and government
56
Inputs
Funds adding, latest quarter117 · 56 pct, sector of 415
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
33
Inputs
Short interest, % of float+8.1% · 33 pct, sector of 530
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Profitability, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CLBT filings, in plain words
Are Cellebrite DI insiders buying or selling CLBT?
In the 180 days to 2026-10-27, Cellebrite DI insiders were net sellers, a net $5.4M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of CLBT?
Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $6.8M of stock; the latest, by David Barter, was filed 2026-10-07.
Read the full summary
In the 180 days to 2026-10-27, Cellebrite DI insiders were net sellers of CLBT, a net $5.4M across purchases and sales reported on Form 4 by 4 sellers. 7% of the 15 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $6.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.